CD4 count improvement following tenofovir to abacavir switch in a patient with persistent lymphopenia despite an undetectable viral load.
Many different antiretroviral regimens can be used as initial therapy for infection with HIV. While all recommended regimens have been shown to be highly effective in suppressing HIV replication to undetectable levels, some differences may exist with regard to the level of immune reconstitution (eg, CD4+ cell population) that occurs. We report a case of a patient with profound and prolonged lymphopenia, despite undetectable HIV RNA levels, that reversed following a switch from a fixed-dose combination of tenofovir/emtricitabine to abacavir/lamivudine in the patient's regimen.
Condoluci
David V
DV
Garden State Infectious Diseases, Voorhees, New Jersey, USA.
Andrews
Maryanne
M
Luber
Andrew D
AD
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology*; D000225:Adenine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D015224:Dideoxynucleosides / Q000627:therapeutic use*; D000068679:Emtricitabine; D005260:Female; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008875:Middle Aged; D063065:Organophosphonates / Q000627:therapeutic use*; D000068698:Tenofovir; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D003841:Deoxycytidine; D015224:Dideoxynucleosides; D000068679:Emtricitabine; D019259:Lamivudine; D063065:Organophosphonates; D000068698:Tenofovir; D000099227:Abacavir